The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
 
Simon Chowdhury
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - Alexion Pharmaceuticals; Array BioPharma; Bristol-Myers Squibb; Eisai; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Exelixis; GlaxoSmithKline; Natera; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - Novartis; Takeda
 
Robert E. Hawkins
No Relationships to Disclose
 
Paola Aimone
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Maurizio Voi
Employment - Novartis
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novartis; Pfizer
 
Naëije Isabelle
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Yi Wu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)